,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-09-03 01:05:00,"On Sep 3, 2014, Zacks Investment Research downgraded Alere Inc. ( ALR ) by a notch to a Zacks Rank #4 (Sell).",0.03339408338069916,0.9268075227737427,0.039798494428396225,negative,-0.8934134244918823
1,2014-09-03 01:05:00,"On Aug 4, Alere reported disappointing 2014 second-quarter results with both the top and the bottom line missing our expectations.",0.02074757032096386,0.9689063429832458,0.010346079245209694,negative,-0.9481588006019592
2,2014-09-03 01:05:00,"Following the earnings release, shares of the company dropped nearly 9.3% till the last closing date.",0.016920387744903564,0.9728299975395203,0.010249597020447254,negative,-0.9559096097946167
3,2014-09-03 01:05:00,The lackluster results have set a negative earnings estimate revision trend for this MA-based provider of rapid diagnostics and health information solutions.,0.0204917024821043,0.9663118124008179,0.013196402229368687,negative,-0.9458200931549072
4,2014-09-03 01:05:00,"For 2014, Alere witnessed two downward estimate revisions over the last one month, with no upward revision, causing the Zacks Consensus Estimate to drop 12.2% to $2.08 per share.",0.017153095453977585,0.9730596542358398,0.009787358343601227,negative,-0.9559065699577332
5,2014-09-03 01:05:00,"For 2015, one estimate moved south during the last 30 days, leading to 2.6% decline in the Zacks Consensus Estimate to $2.59 per share.",0.021359436213970184,0.9696001410484314,0.009040429256856441,negative,-0.9482406973838806
6,2014-09-03 01:05:00,Adjusted earnings per share of 44 cents in the second quarter of 2014 came in 29.0% below the year-ago earnings of 62 cents and missed the Zacks Consensus Estimate by a wide margin of 24.1%.,0.021143879741430283,0.9680565595626831,0.010799548588693142,negative,-0.9469127058982849
7,2014-09-03 01:05:00,"Meanwhile, net revenues declined 3.4% year-over-year to $737.9 million and also missed the Zacks Consensus Estimate by 0.8%.",0.017970899119973183,0.9741647839546204,0.007864286191761494,negative,-0.9561938643455505
8,2014-09-03 01:05:00,"Revenues continue to be impacted by weak U.S. influenza sales and wider-than-expected decline in U.S. healthcare utilization, which primarily affects Alere's U.S. infectious disease revenues.",0.0181917455047369,0.9547735452651978,0.027034731581807137,negative,-0.9365817904472351
9,2014-09-03 01:05:00,"Despite growth across international markets, revenues during the quarter lacked luster.",0.041179779917001724,0.9219093322753906,0.036910876631736755,negative,-0.8807295560836792
10,2014-09-03 01:05:00,Margins and segmental results were also disappointing.,0.01683633215725422,0.9691805839538574,0.013983016833662987,negative,-0.9523442387580872
11,2014-09-03 01:05:00,"Gross margins remain pressurized owing to weak results across higher margin geographies, lower U.S. influenza sales and costs associated with two product recalls made during the second quarter.",0.018801623955368996,0.9621151685714722,0.019083190709352493,negative,-0.9433135390281677
12,2014-09-03 01:05:00,"While net revenues from the Professional Diagnostics segment were supported by the company's recent professional diagnostics acquisitions, it was offset by the disposition of Spinreact in 2013.",0.3917475640773773,0.33594971895217896,0.2723027169704437,positive,0.055797845125198364
13,2014-09-03 01:05:00,"Moreover, a weak contracting season in the second half of 2013 hurt net revenues at the Health Information Solutions segment.",0.018327457830309868,0.9714068174362183,0.01026576291769743,negative,-0.953079342842102
14,2014-09-03 01:05:00,"Nevertheless, the company's Consumer Diagnostics segment is reaping continued success from its joint venture with The Procter & Gamble Company ( PG ).",0.9503600597381592,0.01589602790772915,0.03374388441443443,positive,0.9344640374183655
15,2014-09-03 01:05:00,The long-term expected earnings growth for this stock is pegged lower at 11.0% compared with industry growth of 15.2%.,0.017853647470474243,0.9594147205352783,0.02273157425224781,negative,-0.9415611028671265
16,2014-09-03 01:05:00,"Other Stocks to Consider

Some better-ranked stocks in the medical products industry include ICU Medical, Inc. ( ICUI ), and Symmetry Medical, Inc. ( SMA ).",0.5663686990737915,0.02750171348452568,0.4061295688152313,positive,0.5388669967651367
17,2014-09-03 01:05:00,"ICU Medical sports a Zacks Rank #1 (Strong Buy), while Symmetry Medical carries a Zacks Rank #2 (Buy).",0.4980332553386688,0.023420613259077072,0.4785461723804474,positive,0.47461265325546265
18,2014-09-03 01:05:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
19,2014-09-03 01:05:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
20,2014-09-03 01:05:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
21,2014-09-03 01:05:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
